- E-mailper.omvik@uib.no
- Visitor AddressHaukeland universitetssykehus, Laboratoriebygget5009 Bergen
- Postal AddressPostboks 78045020 Bergen
Academic article
- (2012). Contrasting hemodynamic mechanisms of losartan- vs. atenolol-based antihypertensive treatment: A LIFE study. American Journal of Hypertension. 1017-1023.
- (2011). Changes in subclinical organ damage vs. in Framingham risk score for assessing cardiovascular risk reduction during continued antihypertensive treatment: a LIFE substudy. Journal of Hypertension. 997-1004.
- (2009). Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: The Losartan Intervention For End point reduction in hypertension (LIFE) study. American Heart Journal. 177-184.
- (2009). Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study. Blood Pressure. 348-361.
- (2009). Left ventricular long-axis function in treated haemochromatosis. The International Journal of Cardiac Imaging. 237-247.
- (2009). Left ventricular diastolic function in patients with treated haemochromatosis. Scandinavian Cardiovascular Journal. 32-38.
- (2009). Impact of diabetes on treatment-induced changes in left ventricular structure and function in hypertensive patients with left ventricular hypertrophy. The LIFE study. NMCD. Nutrition Metabolism and Cardiovascular Diseases. 306-312.
- (2009). Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan intervention For Endpoint reduction in hypertension study. Journal of Hypertension. 567-574.
- (2009). Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study. Journal of Hypertension. 567-574.
- (2008). Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE Study. American Heart Journal. 177-184.
- (2008). Losartan compared with atenolol has positive effects on lipid metabolism in patients with hypertension and left ventricular hypertrophy: The LIFE Study. Journal of Hypertension.
- (2007). Reduced exercise capacity in genetic haemochromatosis. European Journal of Cardiovascular Prevention & Rehabilitation. 470-475.
- (2007). Left atrial size and risk of major cardiovascular events during antihypertensive treatment - Losartan intervention for endpoint reduction in hypertension trial. Hypertension. 311-316.
- (2006). Exercise performance during losartan- or atenolol-based treatment in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy). Blood Pressure. 220-226.
- (2005). The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study. The Journal of Clinical Hypertension. 152-158.
- (2005). The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study. Journal of Hypertension. 152-158.
- (2005). The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study. Journal of the American College of Cardiology. 770-775.
- (2005). Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. Hypertension. 46-52.
- (2005). Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension. 198-202.
- (2005). Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. Hypertension. 580-585.
- (2005). Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. Circulation. 1924-1931.
- (2004). The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney International. 1014-1049.
- (2004). Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: The LIFE study. Blood Pressure. 376-384.
- (2004). Hypertensjon og hjertesykdom. Tidsskrift for Den norske legeforening. 802-805.
- (2004). Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. Journal of Hypertension. 1805-1811.
- (2004). Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. Journal of Hypertension. 1805-1811.
- (2004). Blood pressure measurements by the Keito machine. Evaluation versus office blood pressure by physicians. Blood Pressure Monitoring. 167-172.
- (2004). Behandling av høyt blodtrykk hos pasienter med venstre<BR/>ventrikkel-hypertrofi. Tidsskrift for Den norske legeforening. 788-791.
- (2004). Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study. Journal of Human Hypertension. 381-389.
- (2003). The Norwegian office-, home-, and ambulatory blood pressure study (NOHA). Blood Pressure. 211-219.
- (2003). Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. Annals of Internal Medicine. 169-177.
- (2003). Allergi, astma og livsstil - epidemiologisk grunnlag - utbredelse. Fagbladet Allergi i praksis. 7-9.
- (2003). Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Annals of Internal Medicine. 901-906.
- (2002). Twenty-four-hour ambulatory blood pressure monitoring in atrial fibrillation. Blood Pressure Monitoring. 149-156.
- (2002). Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. Journal of Hypertension. 1879-1886.
- (2002). Impact of diastolic Doppler indices on exercise capacity in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy). Journal of Hypertension. 1223-1229.
- (2002). Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. Journal of the American Medical Association (JAMA). 1491-1498.
- (2002). Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. The Lancet. 995-1003.
- (2002). Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. The Lancet. 1004-1010.
- (2001). Renal hemodynamic effects of captopril and doxazosin during slight physical activity in hypertensive patients with type-1 diabetes mellitus. Kidney and Blood Pressure Research. 64-70.
- (2001). A retrospective analysis comparing the costs and cost effectiveness of amlodipine and enalapril in the treatment of hypertension. Managed Care Interface. 82-87.
- (2000). Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy. The LIFE study. American Journal of Hypertension. 899-906.
- (2000). Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy. The LIFE study. American Journal of Hypertension. 899-906.
- (2000). Long-term central hemodynamic effects at rest and during exercise of losartan in essential hypertension. American Heart Journal. 624-630.
- (2000). Long-term central hemodynamic effects at rest and during exercise of losartan in essential hypertension. American Heart Journal. 624-630.
- (2000). Cardiac biochemical markers after cardioversion of atrial fibrillation or atrial flutter. American Heart Journal. 690-694.
- (2000). Cardiac biochemical markers after cardioversion of atrial fibrillation or atrial flutter. American Heart Journal. 690-694.
- (1999). Similar central hemodynamics in salt sensitive and salt resistant hypertensive patients. Blood Pressure. 233-241.
- (1999). Similar central hemodynamics in salt sensitive and salt resistant hypertensive patients. Blood Pressure. 233-241.
- (1999). Reproducibility of salt sensitivity testing using a dictary approach in essential hypertension. Journal of Human Hypertension. 375-384.
- (1999). Cardiac biochemical markers after cardioversion of atrial fibrillation. Scandinavian Cardiovascular Journal. 24.
- (1998). Årsaker til og konsekvenser av mild hypertensjon? Tidsskrift for Den norske legeforening. 4396-4398.
- (1998). The Bergen Blood pressure Study: changes in cardiac structure and function in offspring of hypertensive families. European Heart Journal. 474-474.
- (1998). Konsensus om hypertensjon? Tidsskrift for Den norske legeforening. 3979-3981.
- (1998). Is salt sensitivity a temporary phenomenon? Journal of Hypertension. 150-150.
- (1998). Factors influencing reduction in blood pressure and left ventricular mass in hypertensive type-1 diabetic patients using captopril or doxazosin for months months. American Journal of Hypertension. 1178-1187.
- (1998). Factors influencing reduction in blood pressure and left ventricular mass in hypertensive type-1 diabetic patients using Captopril or Doxazosin for months. American Journal of Hypertension. 1178-1187.
- (1998). Factors Influencing Left Ventricular Mass in Salt Sensitive and Salt Resistant Essential Hypertensive Patients. Blood Pressure. 223-230.
- (1998). Characteristics of 9194 patients with left ventricular hypertrophy. The LIFE study. Hypertension. 989-997.
- (1998). Beta-2 adrenoceptor genetic variation is associated with genetic predisposition to essential hypertension: The Bergen Blood Pressure Study. Kidney International. 1455-1460.
- (1997). Regression of left ventricular hypertrophy in type-1 diabetic patients using doxazosin as antihypertensive therapy @<abstract@>. Journal of Hypertension. 40.
- (1997). Factors influencing LVM in hypertensitive type-1 diabetic patients. Blood Pressure. 197-202.
- (1997). Factors influencing LVM in hypertensitive type-1 diabetic patients. Blood Pressure. 197-202.
- (1997). Angiotensin converting enzyme inhibition and alpha<SUB>1</SUB>-receptor blockade as antihypertensive therapy in type-1 diabetic patients. American Journal of Hypertension. 121A.
- (1996). Factors influencing left ventricular mass in hypertensive type-1 diabetic patients. American Journal of Hypertension. 65A.
Report
- (2000). Hjerteinfarkt (revidert utgave). .
Academic lecture
- (2003). Left atrial size and risk of major cardiovascular events in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE trial).
- (2002). The impact of concomitant diabtes on changes in left ventricular structure and function during antihypertensive treatment (the LIFE study).
- (2000). The effect of losartan treatment on left ventricular hypertrophy in patients with essential hypertension.
- (2000). The effect of losartan treatment on left ventricular hypertrophy in patients with essential hypertension.
- (2000). Reduction in left ventricular mass and blood pressure is not accompanied by improved exercise performance in hypertensive patients with left ventricular hypertrophy.
- (2000). Reduction in left ventricular mass and blood pressure is not accompanied by improved exercise performance in hypertensive patients with left ventricular hypertrophy.
- (1999). Troponin I and T in atrial fibrillation.
- (1999). Cardiac biochemical markers after cardioversion of atrial fibrillation.
- (1997). The alerting reaction to conventional blood pressure measurement is more pronounced in offspring of hypertensive than normotensive parents.
- (1997). Increased alerting reaction to conventional blood pressure measurement in offspring of hypertensive parents.
Non-fiction book
- (2000). Hjerteinfarkt (revidert utgave). Nasjonalforeningen. Det norske råd for hjerte og karsykdommer.
Feature article
- (2004). Hvorfor ikke alltid diuretika? Tidsskrift for Den norske legeforening. 1419-1420.
- (1999). Helsefare på Haukeland sykehus. Bergens Tidende.
- (1998). Will the millimetre of mercury be replaced by the kilopascal? Journal of Hypertension. 1055-1056.
Academic chapter/article/Conference paper
- (2014). Hemodynamics and Hypertension. 14 pages.
- (2000). Pågående multisenterstudier i hypertensjon - faglig medisinsk betydning og konsekvenser for pasienten. 4 pages.
Abstract
- (2005). Influence of hypertension on angiographic findings in patients with angina pectoris. American Journal of Hypertension. 175A.
- (2004). Blood pressure and cardiovascular risk factors in hypertensive patients referred to a regional hospital in Ghana. American Journal of Hypertension. A196.
Poster
- (2003). Comparison of blood pressure measurements by the Keito machine to casual blood pressure measured by physicians.
- (1999). Factors influencing cardiac hypertrophy in type-1 diabetes mellitus.
Academic literature review
- (2009). Central haemodynamics of hypertension. Archives of Medical Science. 220-228.
More information in national current research information system (CRIStin)